pet care
Pet Health Exposed: Elanco's Q1 Surge vs 2025 Data
Elanco’s Q1 2026 earnings rose 18% year-over-year, driven by a surge in preventative pet health sales. The boost reflects a new flea-and-tick vaccine, higher customer retention, and fresh regulatory approvals that widened the revenue base. Investors are now asking what hidden pipeline catalysts are powering this leap. Medical Disclaimer: